title: CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
abstract: OBJECTIVE
  To describe qualitative and quantitative optical coherence tomography (OCT) angiography (OCTA) parameters for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and their applicability as potential clinical trial endpoints.
  
  
  METHODS
  A review of current literature related to the topic of OCTA and AMD.
  
  
  RESULTS
  There are a number of promising OCTA parameters that can be used to diagnose the presence of CNV and to monitor the activity and progression of the lesion, pre- and post-treatment morphological characteristics, CNV dimensions, and automated quantitative parameters such as vessel density.
  
  
  CONCLUSIONS
  The OCTA parameters described in this review have promise for the future development of clinical trial endpoints, but require further validation before they can be widely used.
authors.affiliation: *New England Eye Center, Tufts Medical Center, Boston, Massachusetts; †Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts; ‡Federal University of Goiás, Goiânia, Brazil; and §School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Emily D
authors.initials: ED
authors.lastname: Cole
authors.forename: Daniela
authors.initials: D
authors.lastname: Ferrara
authors.forename: Eduardo A
authors.initials: EA
authors.lastname: Novais
authors.forename: Ricardo N
authors.initials: RN
authors.lastname: Louzada
authors.forename: Nadia K
authors.initials: NK
authors.lastname: Waheed
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D002986:Clinical Trials as Topic; D006801:Humans; D008268:Macular Degeneration / Q000150:complications* / Q000000981:diagnostic imaging; D041623:Tomography, Optical Coherence / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A